ABSTRACT
Background
and Aim: The treatment of choice for relapsed or refractory
Non-Hodgkin Lymphoma (NHL) mainly, is High dose chemotherapy with autologous stem cell transplantation. However, its use is mostly
restricted to patients responding to salvage chemotherapy. In this study, our
aim was to evaluate outcome and toxicity of different treatment modalities of
relapsed and refractory NHL. Patient and Methods: This retrospective study
included 217 patients were diagnosed as refractory or relapsed NHL. Those
patients received different treatment modalities as GDP (Gemcitabine, dexamethasone,
cisplatin), DHAP (Dexamethasone, Cytarabine, and Cisplatin), MINE (Mitoxantrone,
ifosfamide, etoposide and mesna), CHOP (Cyclophosphamide, Doxorubicin, Vincristine
and Prednisone), and CVP (Cyclophosphamide, vincristine and prednisone). Results: The median age of patients in the study was 50 years. Patients who received
DHAP showed ORR of 62%, which was the highest response. The most common adverse
effects were hematological which were more noticed in patients, received CHOP.
Sixty one patients (54.5%) had anemia, 54 patients (48.2%) had neutropenia and 55
patients (49.1%) had thrombocytopenia, but the
difference between the different lines of treatment wasn’t significant p value of 0.95. The median time to relapse is 10 months and the median survival
time is 40 months. The 3-year PFS rates of all patients were 49.3%, while the 3
year OS rates were 54.8%. Conclusion: The overall and PFS didn’t show
any difference between different lines of treatment.